Noha Rashad, Medical Oncology Consultant at Shifa Hospital, shared on LinkedIn:
“ACCTICA-1 trial…
Capecitabine is still the standard of care as adjuvant systemic treatment for resected biliary cancers.
No PFS benefit, numerically longer OS but not statistically significant. And more toxicity for the investigational arm.
So, another negative trial…”
You can also read: ACTICCA-1 at ESMO 2026: Adjuvant Gemcitabine Plus Cisplatin vs Capecitabine in Resected Biliary Tract Cancer
